

1. 10.18097.BMCRM00303\_figure1.png

The structural formulas of approved epidermal growth factor receptor inhibitors used to construct the fragment.

2. 10.18097.BMCRM00303\_figure2.png

The structural formulas of approved 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors used to construct the fragment.

3. 10.18097.BMCRM00303\_figure3.png

The structural formulas of approved dopamine receptor type 2 antagonists used to construct the fragment.

4. 10.18097.BMCRM00303\_figure4.png

The structural formulas of approved muscarinic receptor type 3 antagonists used to construct the fragment.